What is the study drug (KD025)?
The study drug is an investigational tablet designed to target the ROCK2 pathway. Pathways are how cells in the body communicate with each other to help our bodies function. When ROCK2 is overactivated, it may result in inflammation of the skin and damage to internal organs. One goal of the study is to see if targeting ROCK2 can help with the symptoms of scleroderma.
What is an investigational drug?
Investigational drugs are not approved
for public use by regulatory authorities, such as the United States Food and
Drug Administration (FDA) or the European Medicines Agency (EMA). These drugs
cannot be sold in stores or prescribed by doctors. They can only be used for
Have other people used KD025 before?
Yes. Previous clinical studies have researched the safety
and effectiveness of the study drug for other conditions that may also be
caused by a malfunctioning ROCK2 pathway. Findings from these studies suggest
that targeting ROCK2 may reduce inflammation in conditions like scleroderma.